Skip to main content

Advertisement

Table 3 Changes in lipoprotein particles after n-3 PUFA administration measured by nuclear magnetic resonance

From: N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study

Lipoprotein particle Before After P-value
VLDL size (nm) 56.3 ± 7.14 45.2 ± 4.01 < 0.001
LDL size (nm) 20.0 ± 0.306 20.1 ± 0.361 0.154
HDL size (nm) 9.13 ± 0.302 9.17 ± 0.382 0.535
Total VLDL & CM concentrations (nmol/L) 73.6 ± 22.0 75.6 ± 38.5 0.850
 Large VLDL & CM (nmol/L) 10.4 ± 4.31 2.18 ± 1.81 < 0.001
 Medium VLDL (nmol/L) 34.6 ± 11.2 36.5 ± 25.6 0.850
 Small VLDL (nmol/L) 28.7 ± 15.3 36.8 ± 20.7 0.380
Total LDL concentration (nmol/L) 1040 ± 237 995 ± 215 0.266
 IDL (nmol/L) 158 ± 75.8 155 ± 87.5 0.850
 Large LDL (nmol/L) 98.9 ± 145 142 ± 131 0.142
 Small LDL (nmol/L) 780 ± 210 698 ± 170 0.151
Total HDL concentration (nmol/L) 34.2 ± 4.42 32.0 ± 5.31 0.110
 Large HDL (nmol/L) 6.25 ± 2.14 6.74 ± 3.26 0.531
 Medium HDL (nmol/L) 4.73 ± 5.00 3.93 ± 3.60 0.557
 Small HDL (nmol/L) 23.2 ± 4.71 21.3 ± 3.42 0.233
LPIR score 65.1 ± 11.1 40.5 ± 14.8 0.001
GlycA 411 ± 50.5 432 ± 49.1 0.129
  1. Data represent the means ± standard deviation. P-values represent differences observed before and after n-3 PUFA administration. VLDL very low-density lipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, CM chylomicron, IDL intermediate density lipoprotein, LPIR lipoprotein insulin resistance, GlycA glycoprotein acetylation